Raqia Therapeutics is Drug Discovery in United States that focus on transformative chimeric antigen business. Founded in 2016. They cover business area such as developer, liquid and solid tumor, transformative chimeric antigen receptor, multiplexing, titration, modularity, healthcare provider, efficacy, durability, accessibility, life-save construct, patient suffering.
2016
( 10 years old in 2026 )
Transformative Chimeric Antigen
-
Pagliuca Harvard Life Lab
127 Western Avenue
Allston, MA 02134
United States
Private
developerliquid and solid tumortransformative chimeric antigen receptormultiplexingtitrationmodularityhealthcare providerefficacydurabilityaccessibilitylife-save constructpatient suffering
* We use standard office opening hours in near Raqia Therapeutics's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Raqia Therapeutics is Drug Discovery business from United States that founded in 2016 (10 years old in 2026), Raqia Therapeutics business is focusing on Transformative Chimeric Antigen.
Raqia Therapeutics headquarter office and corporate office address is located in Pagliuca Harvard Life Lab 127 Western Avenue Allston, MA 02134 United States.
Raqia Therapeutics was founded in United States.
In 2026, Raqia Therapeutics is currently focus on transformative chimeric antigen sector.
Above is snippet of Google Trends for "transformative chimeric antigen" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Raqia Therapeutics, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
